{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:06:32Z","timestamp":1792343192548,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01162-z","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T08:02:09Z","timestamp":1729238529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Annunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-5883","authenticated-orcid":false,"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4292-1137","authenticated-orcid":false,"given":"Andrea","family":"Anampa-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Reves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montreh","family":"Tavakkoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hansinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Ramakrishnan","family":"Geethakumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/hematology.2022000362","volume":"2022","author":"M Merli","year":"2022","unstructured":"Merli M, Arcaini L. Management of marginal zone lymphomas. Hematology American Society of Hematology Education Program. 2022;2022:676\u201387.","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"1162_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1182\/hematology.2020000157","volume":"2020","author":"A Broccoli","year":"2020","unstructured":"Broccoli A, Zinzani PL. How do we sequence therapy for marginal zone lymphomas? Hematology American Society of Hematology Education Program. 2020;2020:295\u2013305.","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMra2102568","volume":"386","author":"D Rossi","year":"2022","unstructured":"Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med. 2022;386:568\u201381.","journal-title":"N Engl J Med"},{"key":"1162_CR4","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1002\/ajh.26103","volume":"96","author":"JL Vaughn","year":"2021","unstructured":"Vaughn JL, Pinheiro LC, Olszewski A, Epperla N. Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). Am J Hematol. 2021;96:E123\u2013E6.","journal-title":"Am J Hematol"},{"key":"1162_CR5","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, et al. Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018:Jco1800138.","DOI":"10.1200\/JCO.18.00138"},{"key":"1162_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajh.21406","volume":"84","author":"A Broyde","year":"2009","unstructured":"Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin\u2019s lymphoma. Am J Hematol. 2009;84:338\u201343.","journal-title":"Am J Hematol"},{"key":"1162_CR7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.5858\/2010-0741-LER","volume":"135","author":"P Kaur","year":"2011","unstructured":"Kaur P. Nodal marginal zone lymphoma with increased large cells: myth versus entity. Arch Pathol Lab Med. 2011;135:964\u20136.","journal-title":"Arch Pathol Lab Med"},{"key":"1162_CR8","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","volume":"127","author":"C Thieblemont","year":"2016","unstructured":"Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma. Blood. 2016;127:2064\u201371.","journal-title":"Blood"},{"key":"1162_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017;130:1409\u201317.","journal-title":"Blood"},{"key":"1162_CR10","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","volume":"107","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107:4643\u20139.","journal-title":"Blood"},{"key":"1162_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-023-01448-y","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, et al. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. J Hematol Oncol. 2023;16:49.","journal-title":"J Hematol Oncol"},{"key":"1162_CR12","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1182\/bloodadvances.2023010133","volume":"7","author":"N Epperla","year":"2023","unstructured":"Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, et al. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023;7:5038\u201346.","journal-title":"Blood Adv"},{"key":"1162_CR13","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1182\/bloodadvances.2023011288","volume":"7","author":"K Annunzio","year":"2023","unstructured":"Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzm\u00e1n A, et al. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances. 2023;7:6839\u201343.","journal-title":"Blood Advances"},{"key":"1162_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1365-2559.2005.02309.x","volume":"48","author":"A Traverse-Glehen","year":"2006","unstructured":"Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology. 2006;48:162\u201373.","journal-title":"Histopathology"},{"key":"1162_CR15","doi-asserted-by":"crossref","unstructured":"Stueber T, Jaitly V, Moore EM. The clinical significance of increased large cells in marginal zone lymphoma. Human pathology (2023).","DOI":"10.1016\/j.humpath.2023.08.004"},{"key":"1162_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cncr.27773","volume":"119","author":"AJ Olszewski","year":"2013","unstructured":"Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database. Cancer. 2013;119:629\u201338.","journal-title":"Cancer"},{"key":"1162_CR17","first-page":"200","volume":"90","author":"B Petit","year":"2005","unstructured":"Petit B, Chaury MP, Le Clorennec C, Jaccard A, Gachard N, Moalic-Judge S, et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica. 2005;90:200\u20136.","journal-title":"Haematologica"},{"key":"1162_CR18","doi-asserted-by":"crossref","unstructured":"Koh J, Jang I, Choi S, Kim S, Jang I, Ahn HK, et al. Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma. Cancers. 2020;12.","DOI":"10.3390\/cancers12061669"},{"key":"1162_CR19","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1002\/cam4.4702","volume":"11","author":"X Li","year":"2022","unstructured":"Li X, Hong H, Huang H, Zou L, Chen Z, Zhang Z, et al. A novel prognostic nomogram for patients with extragastric mucosa-associated lymphoid tissue lymphoma: a multicenter study. Cancer Medicine. 2022;11:3407\u201316.","journal-title":"Cancer Medicine"},{"key":"1162_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood.2021012386","volume":"139","author":"F Bonfiglio","year":"2022","unstructured":"Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139:732\u201347.","journal-title":"Blood"},{"key":"1162_CR21","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","volume":"128","author":"V Spina","year":"2016","unstructured":"Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, et al. The genetics of nodal marginal zone lymphoma. Blood. 2016;128:1362\u201373.","journal-title":"Blood"},{"key":"1162_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102592","volume":"72","author":"L Arcaini","year":"2024","unstructured":"Arcaini L, Bommier C, Alderuccio JP, Merli M, Fabbri N, Nizzoli ME, et al. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. EClinicalMedicine. 2024;72:102592.","journal-title":"EClinicalMedicine"},{"key":"1162_CR23","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","volume":"95","author":"F Berger","year":"2000","unstructured":"Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon P-A, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950\u20136.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01162-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01162-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01162-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T08:02:51Z","timestamp":1729238571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01162-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01162-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NSG: Research funding: Tessa Therapeutics, Cabaletta, BMS, Regeneron. Honoraria\/consulting\/ad boards for ADC Therapeutics, Genentech, Kite, Novartis, Ono Pharma, BMS, Regeneron, Janssen, Caribou, and Seagen. PT: Honoraria\/consulting\/ad boards for TG Therapeutics, ADC Therapeutics, Genentech, GenMab and Lilly USA. RK: Advisory Board: BMS, Miltenyi, Abbvie, Genmab, Lilly USA, Genentech\/Roche; Grants\/Research Support: BMS. Speakers Bureau: AstraZeneca, BeiGene, Morphosys\/Incyte BC: Research funding: Genentech, Acerta, Triphase, MorphoSys, SeaGen, Millenium, Bristol-Myers Squibb, F Hoffman-La Roche; Advisory Board: Genentech, ADC Therapeutics SKB: Honoraria: Acrotech, Affimed, Daiichi Sankyo, Kyowa Kirin, Janssen, Seagen PRG: PRG: Consultancy services: Kite\/Gilead Pharma, Bristol Myers Squibb (BMS). Advisory board: Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences, Ono Pharma, CRISPR therapeutics, IPSEN Biopharma, and Regeneron Pharmaceuticals NLB: Research funding: ADC Therapeutics, Autolus, BMS, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Merck, Millennium, Pharmacyclics, Affirmed Therapeutics, Dynavax, Gilead, MedImmune, Novartis; Consulting\/Ad board: Kite Pharma, Pfizer, ADC Therapeutics, Roche\/Genentech, Seattle Genetics, BTG, Acerta AJO: Genmab; Precision Bio; Adaptive Biotechnologies; Celldex; Acrotech Biopharma; Schrodinger; TG Therapeutics; Genentech. NE: Research funding: Beigene, Lilly, and Incyte; Speakers Bureau for Beigene and Genentech, Ad boards for ADC Therapeutics, Lilly, and Ipsen; Honorarium from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}